Dra. Mª Jesús Sanz Ferrando
Principal Investigator
Research Group on Inflammation
Presentation
Dr. Sanz is Full Professor at the Department of Pharmacology, University of Valencia since 2009 and co-coordinator of the Inflammation Group at the Institute of Health Research of the University Clinic Hospital of Valencia (INCLIVA). President of the Spanish Society of Pharmacology (2014- 2019) and since 2016, member of the Federation of European Pharmacological Societies (EPHAR) Executive Committee.
Since 1992 her research has been focused in the area of Immunity and Inflammation mainly on the study of the molecular and cellular mechanisms involved in endothelial dysfunction. Nowadays, her group is evaluating the impact of the systemic inflammation associated to different diseases (primary hypercholestetolemia, metabolic syndrome, COPD or menopause) in the development of further cardiovascular disorders (CVD) such as atherosclerosis or abdominal aortic aneurysm. This traslational research has allowed to find new potential biomarkers of CVD and/or new therapeutic interventions to prevent it.
She has been evaluator of the Spanish National Evaluation Agency (ANEP) and other regional agencies. Consequently, she became adjunct to the Coordinator of ANEP (Spanish Ministry of Innovation and Competitiveness, 2009-2013) and since 2018 she is a collaborator of the Spanish Research Council (AEI). Internationally, she has evaluated projects for the Canadian Foundation for Innovation (CFI), the Wellcome Trust, the European Commission (Horizon 2020 projects), etc.
As result of her research she has published around 120 original articles and reviews in relevant peer-reviewed journals and 9 book chapters. 70% of the indexed publications are published in Q1 journals (40% of them in D1 journals). Her h-index is 37. She has supervised 14 PhD students and the work carried out has been continuously funded as a PI in competitive national and regional grants since 1999. She has given around 25 invited lectures and seminars in national and international forums and has made numerous stays in different foreign research centres: more than 3 years at the NHLI of the Imperial College (London, UK), two years at the Immunology Science Research Group of the University of Calgary (Calgary, Canada).

Publications
Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Ascaso P, Palanca A, Martinez-Hervas S, Sanz MJ, Ascaso JF, Piqueras L, Real JT. International Journal of Clinical Practice. 2021 Apr 30;e14302. doi: 10.1111/ijcp.14302. PMID: 33930221
Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction. Rios Navarro C, Hueso Soler L, Diaz Cuevas A, Marcos Garcés V, Bonanad Lozano C, Ruiz Sauri A, Vila Salinas J, Sanz Ferrando M, Chorro Gascó F, Piqueras Ruiz L, Bodí Peris V. Revista espanola de Cardiologia (English ed.). 2021 Feb;74(2):131-139. doi: 10.1016/j.rec.2020.03.013. PMID: 32474003
The nuclear retinoid-related orphan receptor RORalpha controls adipose tissue inflammation in patients with morbid obesity and diabetes. Ortega R, Hueso L, Benito E, Ortega J, Civera M, Sanz M, Real J, Piqueras L. International Journal of Obesity. 2021 Feb 26. doi: 10.1038/s41366-021-00787-5. PMID: 33637954
Pharmacological modulation of redox signaling pathways in disease. Sanz Ferrando M, Alcaraz Tormo M. Free Radical Biology and Medicine. 2020 Sep;157:1-2. doi: 10.1016/j.freeradbiomed.2020.04.003. PMID: 32272159
Postprandial triglyceridemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects. Moreno-Perez B, Benito E, Civera M, Alabadi B, Martinez-Hervas S, Peiro M, Gonzalez-Navarro H, Piqueras L, Jesus Sanz M, Ascaso J, Real J. International Journal of Clinical Practice. 2020 Oct 21;e13776. doi: 10.1111/ijcp.13776. PMID: 33089594
Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation. Collado A, Marques P, Domingo E, Perello E, González-Navarro H, Martinez-Hervás S, Real JT, Piqueras L, Ascaso JF, Sanz MJ. Journal of Clinical Medicine. 2019 Jan; 8(1): 18. PMID: 30583563
Polycerasoidol, a Natural Prenylated Benzopyran with a Dual PPAR alpha/PPAR gamma Agonist Activity and Anti-inflammatory Effect. Bermejo A, Collado A, Barrachina I, Marqués P, El Aouad N, Franck X, Garibotto F, Dacquet C, Caignard DH, Suvire FD, Enriz RD, Piqueras L, Figadère B, Sanz MJ, Cabedo N, Cortes D. Journal of Natural Products. 2019 Jul 26;82(7):1802-1812. doi: 10.1021/acs.jnatprod.9b00003. PMID: 31268307
SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Anciotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice. Ortega R, Collado A, Selles F, Gonzalez-Navarro H, Sanz MJ, Real JT, Piqueras L. Arteriosclerosis Thrombosis and Vascular Biology. 2019 Aug;39(8):1614-1628. doi: 10.1161/ATVBAHA.119.312659. PMID: 31294626
Projects
Referencia: PROMETEO/2019/032
Título: Una aproximación translacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos
Entidad Financiadora: Conselleria de Educación Cultura y Deporte
Investigador principal: Mª Jesús Sanz Ferrrando
Duración: 2020 – 2023
Presupuesto: 211.736 €
Referencia: SAF2017-89714-R
Título: Modulación farmacológica del sistema inmune como diana clave en la prevención de la enfermedad cardiovascular asociada a desordenes metabólicos. Síntesis de fármacos novedosos
Entidad Financiadora: Ministerio de Economía y Competitividad
Investigador principal: Mª Jesús Sanz Ferrando, Juan F. Ascaso Gimilio
Duración: 2018 – 2021
Presupuesto: 205.700 €